HC Wainwright Reiterates “Buy” Rating for Replimune Group (NASDAQ:REPL)

HC Wainwright reaffirmed their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report released on Friday morning,Benzinga reports. They currently have a $17.00 price objective on the stock.

A number of other research firms have also commented on REPL. Roth Capital raised Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Stock Performance

Shares of REPL opened at $13.26 on Friday. The company has a 50-day moving average of $11.59 and a two-hundred day moving average of $9.76. The stock has a market cap of $907.25 million, a P/E ratio of -4.35 and a beta of 1.19. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, research analysts predict that Replimune Group will post -3.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its stake in Replimune Group by 575.1% during the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP increased its position in Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. State Street Corp raised its holdings in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after buying an additional 1,182,181 shares during the period. Baker BROS. Advisors LP lifted its position in Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.